Merck + Co., Inc.

Jiunn H Lin

Steven M Pitzenberger

Harri G Ramjit

Edgar H Ulm

Joseph P Vacca

Paul J Deutsch

Jeffrey A Chodakewitz

William D Ju

Kuang C Yeh

The combination of the HIV protease inhibitor Compound A and one or more nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, or protease inhibitors is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of AIDS, either as compounds, pharmaceutically acceptable salts or esters, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Combination therapy for the treatment of AIDS

A metabolite of the known anxiolytic agent, 7-chloro-5,6-dihydro-3-(5-isopropyl-1,2,4-oxadiazol-3-yl)-5-methyl-6-oxo-4 H-i midazo[1,5a][1,4]benzodiazepine is a 1,2-dihydroxy derivative of the isopropyl moiety and is itself an anxiolytic agent of greater activity than its substrate.

7-chloro-5,6-di

A metabolite of the known anxiolytic agent, 7-chloro-5,6-dihydro-3-(5-isopropyl-1,2,4-oxadiazol-3-yl)-5-methyl-6-oxo-4 H- imidazo[1,5a][1,4]benzodiazepine is a 2-hydroxy derivative of the isopropyl moiety and is itself an anxiolytic agent.

7-chloro-5,6-dihydro-3-(5-(2-hydroxy-isoprop

Growing community of inventors

Ambler, PA, United States of America

Jiunn H Lin